Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study
References (43)
- et al.
Elevation of C-reactive protein in “active” coronary artery disease
Am J Cardiol
(1990) - et al.
Comparison of effects of high (80 mg) versus low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing
Am J Cardiol
(2007) - et al.
C-reactive protein contributes to the hypercoagulable state in coronary artery disease
J Thromb Haemost
(2006) - et al.
Strong decrease of high sensitivity C-reactive protein with highdose atorvastatin in patients with type 2 diabetes mellitus
Atherosclerosis
(2003) - et al.
Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia
Am J Cardiol
(2002) Low-density lipoproteindependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: A metaanalysis
J Am Coll Cardiol
(2007)- et al.
Cytokines in atherosclerosis: Pathogenic and regulatory pathways
Physiol Rev
(2006) - et al.
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina
N Engl J Med
(1994) - et al.
Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis
Circulation
(2006) - et al.
Inflammation as a cardiovascular risk factor
Circulation
(2004)
Effect of C-reactive protein on vascular cells: Evidence for a proinflammatory, proatherogenic role
Curr Opin Nephrol Hypertens
(2005)
C-reactive protein: Risk marker or mediator in atherothrombosis?
Hypertension
(2004)
Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
Lancet
(2005)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
JAMA
(1998)
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
N Engl J Med
(2001)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
N Engl J Med
(1996)
Long-term efton fects of pravastatin on plasma concentration of C-reactive protein
Circulation
(1999)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
N Engl J Med
(2004)
C-reactive protein levels and outcomes after statin therapy
N Engl J Med
(2005)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial
JAMA
(2004)
A tale of two trials: A comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22
Circulation
(2006)
Cited by (74)
Estimating localization of various statins within a POPC bilayer
2021, Chemistry and Physics of LipidsEpicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium
2018, Journal of the American College of CardiologyAtorvastatin and c-reactive protein concentrations in overweight women with Polycystic ovary syndrome
2016, Clinica e Investigacion en Ginecologia y Obstetricia
- *
The CAP Investigators are listed in the Acknowledgments.
Copyright © 2008 Published by Elsevier Inc.